Showing 311-320 of 3511 results for "".
- Zasocitinib Outperforms Deucravacitinib in Phase 3 Head-to-Head Psoriasis Trialhttps://practicaldermatology.com/news/zasocitinib-outperforms-deucravacitinib-in-phase-3-head-to-head-psoriasis-trial/2488633/Investigational oral tyrosine kinase 2 (TYK2) inhibitor zasocitinib (TAK-279) demonstrated superior skin clearance compared with deucravacitinib in adults with moderate-to-severe plaque psoriasis, according to phase 3 data presented at the European Academy of Dermatology & Venereology (EADV)
- New LATITUDE Data Detail Zasocitinib Efficacy, Durability in Plaque Psoriasishttps://practicaldermatology.com/news/new-latitude-data-detail-zasocitinib-efficacy-durability-in-plaque-psoriasis/2488590/New Phase 3 data presented at the European Academy of Dermatology & Venereology (EADV) Congress 2026 showed higher skin clearance rates with investigational oral tyrosine kinase 2 (TYK2) inhibitor zasocitinib (TAK-279) compared with deucravacitinib in adults with modera
- Olumiant Gains FDA Approval for Severe Alopecia Areata in Patients 12 and Olderhttps://practicaldermatology.com/news/olumiant-gains-fda-approval-for-severe-alopecia-areata-in-patients-12-and-older/2488595/The FDA has approved Eli Lilly and Company’s Olumiant (baricitinib) for patients aged 12 years and older with severe alopecia areata (AA), expanding the oral Janus kinase (JAK) inhibitor’s US indication to adolescents, according to an announcement from the manufacturer. The
- FDA Approves First Treatment for Ataxia-Telangiectasiahttps://practicaldermatology.com/news/fda-approves-first-treatment-for-ataxia-telangiectasia/2488536/The US Food and Drug Administration (FDA) has approved Aqneursa (levacetylleucine; IntraBio) for the treatment of adults and pediatric patients with ataxia-telangiectasia (A-T) who weigh at least 15 kg, providing the first FDA-approved treatment for the rare multisystem disorder. A-T is pr
- Consensus Statement: JAK Inhibitors Emerge as Primary Therapy for Severe Alopeciahttps://practicaldermatology.com/news/consensus-statement-jak-inhibitors-emerge-as-primary-therapy-for-severe-alopecia/2488332/A US expert consensus provides a standardized treatment framework for adults with severe alopecia areata (AA), placing oral Janus kinase (JAK) inhibitors at the center of long-term disease management.
- INTerpath-001: Intismeran Plus Pembrolizumab Meets Dual Phase 3 Melanoma Endpointshttps://practicaldermatology.com/news/intismeran-plus-pembrolizumab-meets-dual-phase-3-melanoma-endpoints/2488176/Merck and Moderna reported positive topline results from the phase 3 INTerpath-001 trial evaluating intismeran autogene (V940; mRNA-4157) plus pembrolizumab (Keytruda) as adjuvant therapy for completely resected stage IIB-IV cutaneous melanoma. The individualized mRNA-based neoantigen ther
- ASDS Launches Financial, Technology Retreat for Dermatologistshttps://practicaldermatology.com/news/asds-launches-financial-technology-retreat-for-dermatologists/2488019/The American Society for Dermatologic Surgery (ASDS) is broadening its educational portfolio with the debut of $kin in the Game, a new financial and technology literacy retreat designed exclusively for dermatologists. The two-day program, developed in collaboration with Wilmington Trust,
- Researchers Recommend Refined Trial Design for Pediatric Vitiligo JAK Studieshttps://practicaldermatology.com/news/letter-highlights-trial-design-considerations-in-pediatric-vitiligo/2487858/Correspondence in the Journal of the American Academy of Dermatology asked for caution when interpreting findings from a recent trial evaluating oral Janus kinase (JAK) inhibitors in combination with 308-nm excimer laser th
- Takeda Reports Positive Phase 3 Results for Oral TYK2 Inhibitor Zasocitinibhttps://practicaldermatology.com/news/takeda-reports-positive-phase-3-results-for-oral-tyk2-inhibitor-zasocitinib/2487546/Takeda announced positive topline results from the Phase 3 LATITUDE Atlas (TAK-279-PsO-3004) trial, a head-to-head study evaluating the investigational oral tyrosine kinase 2 (TYK2) inhibitor zasocitinib (TAK-279) against deucravacitinib in adults with moderate-to-severe plaque psoriasis.
- Oral Nicotinamide Linked to Fewer Skin Cancers and Lower Treatment Costshttps://practicaldermatology.com/news/oral-nicotinamide-linked-to-fewer-skin-cancers-and-lower-treatment-costs/2487444/Oral nicotinamide may offer a cost-effective strategy for preventing keratinocyte carcinoma (KC) in patients at high risk for developing multiple skin cancers, according to a new economic evaluation conducted within the Veterans Health Administration (VHA) published in JAMA Dermatology.<